Testing version — LOERadar is in active testing. Features and data may change.
TEVETEN (EPROSARTAN MESYLATE) | LOERadar
TEVETEN
NDA
EPROSARTAN MESYLATE | N020738 | ABBVIE INC
3 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
#004 — EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
0 patents0 exclusivities▴
TABLET;ORAL | Approved: Dec 22, 1997
No patent or exclusivity listings for this strength.
#005 — EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Dec 22, 1997
#006 — EQ 600MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**